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Key Points
• Differentiation of CLL cells




(CpG-ODN) is variable and
linked to PRDM1 induction.
• The failure of CLL cells to
express or induce PRDM1
correlates with anergy.
Despite antigen engagement and intact B-cell–receptor (BCR) signaling, chronic
lymphocytic leukemia (CLL) cells fail to undergo terminal differentiation.We hypothesized
that such failure may be due to anergy, as CLL cells exhibit variable levels of
nonresponsiveness to surface IgM stimulation that is reversible in vitro. Moreover, anergy
is associated with reduced differentiation capacity in normal B cells. We investigated
responses of CLL cells to two potent differentiation-promoting agents, IL-21 and cytosine
guanine dinucleotide-enriched oligo-deoxynucleotides. The induction of PR domain-
containing protein 1 (PRDM1; also known as Blimp-1), a critical regulator of plasmacytic
differentiation, by these agentswas closely correlated but variedbetween individual cases,
despite functionally intact IL-21 receptor– and Toll-like receptor 9–mediated signal
transducer and activator of transcription 3, and nuclear factor-kB pathways. PRDM1
induction was inversely correlated with the extent of anergy as measured by the ability
to mobilize intracellular Ca21 following BCR crosslinking. PRDM1 responsiveness was
associated with other markers of differentiation and proliferation but not with differences
in apoptosis. The ability to induce PRDM1 did correlate with differential transcriptional and epigenetic regulation of the PRDM1
gene. These studies extend our understanding of CLL pathobiology, demonstrating that reduced differentiation capacity may be
a consequence of anergy. Epigenetic drugs may offer possibilities to reactivate PRDM1 expression as part of novel differentiation
therapy approaches. (Blood. 2014;123(21):3277-3285)
Introduction
Chronic lymphocytic leukemia (CLL) is a malignancy of B lympho-
cytes that retain dependency on extracellular stimuli for their survival
and behavior. Two major CLL subsets have been identiﬁed which
arise at distinct stages of B-cell differentiation and are characterized
by varying levels of somatic hypermutation of immunoglobulin (Ig)
V-genes.1 Importantly, these subsets exhibit very different clinical
behavior. CLLwith unmutatedV-genes (U-CLL) appears to develop
from naive B cells of the natural antibody repertoire with speciﬁcity
for common pathogens and has a signiﬁcantly worse prognosis
compared with CLL with mutated V-genes (M-CLL).2-5 Further
support for a role of antigen stimulation in CLL is provided by the
presence of biased V-gene usage in both subsets and the presence of
conserved sequence motifs within the complementarity determining
region 3s of CLL-derived B-cell receptors (BCRs).6-8 Putative CLL
antigens have been identiﬁed, including self-antigens, or antigens
derived from common pathogens including viruses, bacteria, and
fungi.9 The idea that BCR signaling is important in CLL is supported
by recent clinical evidence describing dramatic responses following
the administration of BCR-associated signaling kinase inhibitors.10
The identiﬁcation of altered surface IgM (sIgM) glycosylation
and “endocytosis in vivo,” whereby sIgM expression and signal
capacity are variably down-modulated in circulatingmalignant cells,
demonstrates that antigen engagement is on-going in most, if not all,
CLL.10,11 The major consequence of chronic antigen engagement
appears to be the induction of anergy,12,13 a mechanism of tolerance
in normal B cells whereby autoreactive cells are rendered non-
responsive to activation via their cell surface BCRs due to antigen
stimulation in the absence of supporting secondary signals.14 CLL
anergy is associated with strong down-modulation of sIgM expres-
sion and signaling capacity, elevated phosphorylation of extracel-
lular signal-regulated kinases (ERK), and increased activation of
nuclear factor of activated T cells (NFAT).12,13 Similar to anergy in
normal B cells,15 CLL anergy is at least partly reversible, as culture
of CLL cells in vitro results in recovery of sIgM expression and
function, and reduced basal ERKphosphorylation.12,16Anergy ismost
apparent in M-CLL and is associated with good prognosis.12
However, in some cases, possibly low levels of “positive” signaling
leading to induction of cell proliferation- and survival-promoting
pathways appears to tip the balance of response toward progressive
disease. For example, the pro-proliferation protein MYC and the
survival protein myeloid cell leukemia sequence 1 (MCL1), which
are induced following sIgM stimulation in vitro, are more highly
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expressed in circulating blood cells in U-CLL compared with
M-CLL.17-20 In normal B cells, anergy is associated with reduced
differentiation in response to a range of stimuli.14 This lack of response
presumably acts to prevent the production of potentially damaging
autoantibodies. Previous studies have shown that CLL cells exhibit
varied capacity to undergo differentiation.21-23 However, the mecha-
nismthat underlies this variation indifferentiationcapacityandwhether
this is linked to the anergic phenotype of CLL cells is unknown.
In this study, we have investigated the responses of primary
CLL samples to two factors, which can promote differentiation of
normalBcells, the cytokine IL-2124 andcytosineguaninedinucleotide-
enriched oligo-deoxynucleotides (CpG-ODN)25; the latter acting via
the pattern recognition receptor, Toll-like receptor (TLR) 9.26 We
demonstrated that CLL anergy, deﬁned by reversible down-
modulation of sIgM signaling capacity, is closely associated with
reduced differentiation responses to either IL-21 or CpG-ODN.
Reduced differentiation capacity, in turn, was associated with
transcriptional repression of the PRDM1 gene which encodes PR
domain-containing protein 1 (PRDM1; also known as Blimp-1),
a major positive regulator of plasma cell (PC) differentiation.27,28
These results provide new insight into the biology of CLL and
mechanismsof anergy regulation inboth normal andmalignantB cells.
Patients, materials, and methods
Cell preparation and culture
This study had approval from the Liverpool Research Ethics Committee, and
CLL cells were isolated from the peripheral blood of consenting donors (see
supplemental Table 1 on the Blood Web site). The study was conducted in
accordance with the Declaration of Helsinki. Normal B cells were obtained
from buffy coats (Liverpool National Blood Service). Cryopreserved CLL
cells from the University of Liverpool Leukemia Tissue Bank were thawed
and used as previously described.29 For CLL samples which comprised
,95%malignant (CD51CD191) cells and for all normalBpreparations, cells
were puriﬁed (to.95%CD51CD191 cells) using negative selection (MACS
system;Miltenyi Biotec). Cells were cultured at 37°Cwith a density of 33 106
cells/mL in culture media (RPMI-1640 [Sigma-Aldrich] supplemented with
0.5% [w/v] bovine serum albumin, 2 mM L-glutamine, 100 units/mL
penicillin, and 100mg/mL streptomycin). IGHV gene analysis was performed
as previously described.30
Reagents
The antibodies and primers used in this study are listed in supplemental
Table 2. IL2 and IL-21 were from Invitrogen, type B CpG-ODN 2006 was
from InvivoGen, and soluble recombinant human CD40 ligand (CD40L)
was from Axxora (UK) Ltd. Phorbol-12-myristate-13-acetate (PMA) and
ionomycin were from Sigma-Aldrich. Secreted Ig was quantiﬁed using
human IgM, IgG, or IgA enzyme-linked immunosorbent assay (ELISA)
quantiﬁcation sets (Bethyl Laboratories).
Morphology
After culture for 5 days, nonapoptotic CLL cells were negatively puriﬁed
using MACS puriﬁcation and cytospun. Apoptotic cells were identiﬁed using
ﬂuorescein isothiocyanate-conjugated Annexin V, and then removed using
antiﬂuorescein isothiocyanate beads. Images were obtained using the
Nikon ACT-1 v2.63 microscope software at 3100 magniﬁcation.
Nuclear factor-kB activation
Nuclear factor-kB (NF-kB) activity wasmeasured using the TransAMNF-kB
p65 ELISA kit (active motif) and a modiﬁed nuclear isolation method. Nuclei
were extracted by lysing cells for 5minutes on ice in phosphate-buffered saline
containing 0.5% NP-40, 2 mM ethylenediaminetetraacetic acid, and protease
inhibitors; 2 mg of the extract was added to each ELISA well.
Additional experimental details for analysis of intracellular Ca21 (iCa21)
mobilization, immunoblotting, RNA analysis, culture conditions involving
soluble and immobilized CD40L stimulation, and chromatin immunoprecip-
itation (ChIP) are provided in the supplemental Methods.
Results
sIgM anergy in CLL cells is associated with reduced
differentiation capacity
B-cell anergy is characterized by reduced anti-IgM–induced iCa21
mobilization in both mouse models14 and primary CLL cells.12
Therefore, to investigate the potential links between anergy and
differentiation capacity, we ﬁrst characterized anti-IgM–induced
iCa21 mobilization in a cohort of 24 CLL samples (14 U-CLL and
10 M-CLL; supplemental Table 1). As previously described,12
iCa21 response was highly variable between individual samples.
The percentage of cells within the malignant clone that were re-
sponsive to sIgM stimulation varied from 0% to 65%, and 17 of 24
samples were considered as signaling responsive, based on the pre-
viously deﬁned cutoff of 5% responding cells.12 Thus, our analysis
conﬁrmed previous studies that identiﬁed variable levels of sIgM
anergy in primary CLL samples. Analysis of additional samples
obtained from 2 patients at later time points (10 months for case 2;
3months for case 9) conﬁrmed that iCa21 signaling responses were
relatively stable during the course of the disease (supplemental
Table 1).
We next investigated the ability of IL-21 to induce differentiation
in vitro in these CLL samples. Induction of PRDM1 expression was
used as a surrogate marker for the ability of CLL cells to differentiate
insofar as this transcriptional repressor is both essential and sufﬁcient
for PC differentiation.27,28 PRDM1 expression was analyzed using
immunoblotting to resolve the PRDM1a and b isoforms, which
are generated by alternative promoter usage and are functionally
distinct. Whereas PRDM1a, a transcriptional repressor, is a positive
regulator of differentiation, repressive functions are absent in
PRDM1b.31 Figure 1A shows representative results of PRDM1
immunoblot analysis of unstimulated PC leukemia (PCL) cells,
and unmanipulated M-CLL and U-CLL samples. PCL cells were
analyzed to conﬁrm the selectivity of the antibody, and as expected,
these cells expressed readily detectable levels of both the
PRDM1a and b isoforms (97 and 80 kDa, respectively), although
expression of PRDM1a was substantially higher than PRDM1b.
In contrast, unstimulated CLL samples expressed little or no PRDM1
protein. Treatment of CLL cells with IL-21 led to variable induc-
tion of PRDM1 protein expression in individual cases. Some cases
showed little or no change, whereas others exhibited signiﬁcant up-
regulation after stimulation compared with untreated controls. The
median induction of PRDM1awas 2.05-fold (range5 0.75 to 5.68;
supplemental Figure 2 and supplemental Table 1), and using a
twofold increase as a cutoff, 14 of 26 cases were classiﬁed as
responsive. Figure 1B shows representative results obtained with
one IL-21 responsive and one IL-21 nonresponsive sample treated
with various concentrations of IL-21. PRDM1awas inducedmuch
more strongly than PRDM1b in responsive samples. Importantly,
densitometric quantitation of the immunoblots demonstrated that the
fold-induction of PRDM1a expression, following treatment with
IL-21, was positively correlated with the extent of anti-IgM–induced
iCa21mobilization, regardless of whether PRDM1 responses were
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considered as a continuous variable (Figure 1Ci; P5 .0001) or were
dichotomized around the twofold cutoff to deﬁne samples as
“responsive” or “nonresponsive” (Figure 1Cii; P5 .003).
Further experiments were performed to characterize in more
detail, the effect of IL-21 on PRDM1 expression inCLL samples. In
IL-21 responsive samples, PRDM1 induction was observed within
16 hours following treatment with 10 to 50 ng/mL of IL-21, al-
though maximal induction was observed after 4 days (Figure 1B
and supplemental Figure 1). However, PRDM1 was not induced in
nonresponsive CLL samples even in cells that were exposed to
substantially higher cytokine concentrations (200 ng/mL; Figure 1B)
or longer incubation times (supplemental Figure 1). PRDM1 induc-
tion was analyzed in an additional 40 samples, so that a total of 66
samples were analyzed following treatment with IL-21 (50 ng/mL)
for 16 hours (supplemental Figure 2). Based on the twofold cutoff,
32% (21 of 66) of samples were considered to be “responsive” for
IL-21–induced PRDM1 expression. Similar to iCa21 responses,
the responsiveness of PRDM1 to IL-21–induced expression was
also relatively stable in repeat samples obtained at later disease
stages, including the 2 patients analyzed for anti-IgM responses
(supplemental Figure 2 and supplemental Table 1).
We also investigated responses to a second differentiation-inducing
factor, CpG-ODN, to determine whether variable differentiation
responses were speciﬁc to IL-21 or represented a broader variation
in differentiation capacity. Thirty-eight CLL sampleswere cultured
for 16 hours with IL-21, CpG-ODN, or left untreated as a control,
and PRDM1 induction was analyzed using immunoblotting. Similar
to IL-21 responses, induction of PRDM1 following treatment with
CpG-ODNwas variable between samples (Figure 2A). Themaximal
induction of PRDM1 was detected in cells treated with 0.1 to
0.5 mg/mL CpG-ODN (Figure 2B), and in general, CpG-ODN in-
duced higher levels of PRDM1 expression compared with IL-21
(Figure 2A). There was a close correlation between the ability of
IL-21 and CpG-ODN to induce PRDM1 expression in individual
samples (P5 33 1026; R5 0.66), and, similar to IL-21, the ability
of CpG-ODN to induce PRDM1 expression was associated with
the extent of anti-IgM–induced iCa21mobilization (P5 .04; R5 0.64)
(Figure 2Ci-ii). Thus, CLL anergy, as deﬁned by lack of sIgM
responsiveness,12 is associated with reduced differentiation capacity
in response to robust PC-inducing stimuli that act by independent
signaling pathways.
The heterogeneous effects of IL-21 or CpG-ODN on PRDM1
induction are linked to proliferation but not survival
Previous studies have demonstrated that IL-21 and CpG-ODN
modulate both cell survival and proliferation in CLL cells32-35 and it
was important to probe the relationship between variable effects on
PRDM1 induction and these responses. To address this, we selected
a cohort of samples that were either responsive or nonresponsive to
IL-21/CpG-ODN (based on PRDM1 induction), and investigated the
effects of these agents on survival and proliferation.
Figure 1. Induction of PRDM1 following treatment with IL-21 in CLL cells
correlates with anergy. (A) Basal (ie, unstimulated) levels of PRDM1 protein in
M-CLL and U-CLL samples (n 5 5 each). A PCL sample was used as a positive
control. n.s.: nonspecific band detected by the PRDM1 antibody. b-actin was
analyzed as a loading control. (B) PRDM1 induction in representative “responsive”
(R) and “non-responsive” (NR) CLL samples after 2 days in culture with the indicated
concentrations of IL-21 (n 5 3). (C) Correlation of PRDM1a protein induction in cells
treated with 50 ng/mL IL-21 for 16 hours. The maximum percentage of cells that
showed increased iCa21 following anti-IgM stimulation: (i) shows linear correlation
between these variables, and (ii) shows significant statistical difference in iCa21
responsiveness between PRDM1 NR (#twofold induction) and R (.twofold
induction) CLL samples (n 5 26). Fold induction of PRDM1a was calculated as
a ratio by western blot densitometry between the IL-21–treated and untreated
samples. The results of statistical evaluation are shown, (i) Pearson’s coefficient,
and (ii) Mann-Whitney U test.
Figure 2. CpG-ODN–mediated induction of PRDM1 is variable and correlates
with IL-21 responsiveness in individual CLL cases. (A) Western blot showing
levels of PRDM1 protein in representative responsive and nonresponsive CLL clones
after being left untreated or following treatment with either IL-21 (21; 50 ng/mL)
or CpG-ODN (CpG; 0.5 mg/mL) for 16 hours (n 5 38). (B) PRDM1 induction in
representative responsive and nonresponsive samples after 2 days in culture with
indicated concentrations of CpG-ODN (CpG) (n 5 38). (C) PRDM1 induction
following 16 hours exposure to CpG-ODN correlates with: (i) PRDM1-induction after
16 hours IL-21 treatment, and (ii) iCa21 responsiveness following anti-IgM stim-
ulation. Induced PRDM1a was calculated by subtracting untreated from treated
measurements by western blot densitometry. Fold PRDM1 induction was calculated
as in Figure 1C. The results of statistical evaluation are shown, (i) Spearman’s
coefficient, and (ii) Pearson’s coefficient.
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Consistent with previous studies,23,32,34 we found that the effects
of IL-21 on CLL-cell survival in our cohort were highly variable
(induction of apoptosis, survival, or no effect). There was no clear
relationship between IL-21–induced apoptosis/survival and PRDM1
responsiveness (supplemental Figure 3A-B; P 5 .153). Responses
to CpG-ODN were more consistent with enhanced survival in all
samples tested, regardless of their responsiveness to CpG-ODN–
induced PRDM1 expression (P 5 1.0 for increase in cell survival
in responsive and nonresponsive samples; supplemental Figure 3B).
Overall, these results show no clear relationship between PRDM1
inducibility and effects on survival, indicating that these responses
are uncoupled. Thus, the failure to induce PRDM1 expression in
nonresponding samples cannot simply be a consequence of induction
of apoptosis in a subset of samples.
Similar experiments were performed to investigate the effects of
IL-21 and CpG-ODN on proliferation in responsive/nonresponsive
samples (supplemental Figure 3C). Interestingly, both IL-21 and
CpG-ODN promoted higher proliferation rates in PRDM1 respond-
ing clones in contrast to nonresponsive cases (IL-21, P 5 .02;
CpG-ODN, P5 .05).
Co-stimulation does not overcome reduced PRDM1 responses
in CLL cells
Normal B cells require co-stimulation for maximal induction of
PRDM1 expression following treatment with IL-21 or CpG-
ODN.24,25 We, therefore, determined whether co-stimulation
using CD40L and/or anti-IgM overcame the reduced differenti-
ation responses of anergic CLL cells. We compared the responses
of CLL cells to those of total (CD191) and memory (CD191
CD271) normal B cells obtained from healthy donors. As pre-
viously demonstrated,24 IL-21 alone modestly induced PRDM1
in both normal total and memory B cells (Figure 3A). IL-21–induced
PRDM1 expression was enhanced by co-stimulation with CD40L
or anti-IgM (CD40L .anti-IgM), but the addition of both CD40L
and anti-IgM resulted in lower levels of IL-21–induced PRDM1
protein compared with co-stimulation with CD40L alone (Figure 3B,
lanes 10-12). Compared with normal B cells, IL-21 alone induced
higher levels of PRDM1 expression in responsive CLL samples
(Figure 3A, lanes 2, 4, and 6). Co-stimulation with anti-IgM
(Figure 3B, lanes 6 and 7) also enhanced IL-21–induced PRDM1
expression in responsive CLL samples, consistent with the
retained IgM-responsiveness of these samples (n 5 4). However,
IL-21 nonresponsive CLL cells had considerably less PRDM1
induction upon addition of CD40L or anti-IgM (either alone or in
combination) compared with responsive cases (Figure 3B lanes 3-5).
Similar results were obtained for both soluble and immobilized
CD40L stimulation of CLL samples (not shown). Comparable to
IL-21, anti-IgM co-stimulation enhanced CpG-ODN–induced
PRDM1 expression in differentiation competent samples, but had
little or no effect in nonresponsive samples (Figure 3C).
Reduced PRDM1 induction in anergic CLL cells is reflected by
a block in differentiation and Ig secretion
To conﬁrm that differences in induction of PRDM1 reﬂected bona
ﬁde differences in differentiation, we characterized Ig secretion,
surface phenotype, and morphologic changes of CLL cells treated
with IL-21 in the presence or absence of co-stimulation. In samples
that were competent for induction of PRDM1, we detected increased
secretion of IgM (but not IgG or IgA, not shown) following treatment
with IL-21 for 5 days, consistent with differentiation (Figure 4A). By
contrast, IgM secretion was not increased in samples that were not
capable of increasing PRDM1 expression following treatment with
Figure 3. Reduced differentiation capacity in CLL samples is not overcome
by additional co-stimuli. (A) Induction of PRDM1 protein in normal B cells
(CD191CD271 [memory normal B] and total CD191 [normal B]) after 2 days of
treatment with IL-21, compared with levels seen in representative responsive and
nonresponsive CLL samples (n 5 3). (B) PRDM1 expression in a representative
nonresponsive CLL clone and normal B-cell (CD191) sample after 2 days of
treatment with IL-21 6 anti-IgM 6 CD40L. The lysate of a responsive CLL clone
treated for 2 days with IL-21 6 anti-IgM is included in each western blot for
comparison (right hand lanes) (n 5 4). (C) PRDM1 induced in representative
responsive and nonresponsive CLL samples after 2 days of treatment with
CpG-ODN 6 anti-IgM (n 5 4).
Figure 4. Induction of PRDM1 in responsive CLL samples correlates with
increased differentiation. (A) Secreted IgM levels after 5 days of treatment of
responsive (R) and nonresponsive (NR) CLL samples with IL-21. (B) Morphology of
representative responsive and nonresponsive CLL samples (n 5 3 each) examined
directly ex vivo (T0), after 5 days in culture medium alone (untreated), or after 5 days of
stimulation by IL-21 with and without co-stimuli (anti-IgM, CD40L, and IL-2) (3100
magnification; Nikon ACT-1 v2.63 microscope software Giemsa staining).
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IL-21 or CpG-ODN. Despite the production of increased IgM, there
were no morphologic changes characteristic of PC differentiation in
CLL cells treated with IL-21 alone (Figure 4B). However, morpho-
logic changes were observed in some samples stimulated with IL-21
plus CD40L, anti-IgM, and IL-2. Like IgM secretion, morphologic
changes were observed only in samples that were competent for
induction of PRDM1.Despite changes inmorphology, CLL cells did
not acquire the classical surface PC phenotype (CD38high, CD27high,
IgDlow, CD20low), whereas this phenotype was observed in ap-
proximately one-third of normal B cells following treatment with the
same stimuli (supplemental Figure 4). Overall, these results conﬁrm
that impaired induction of PRDM1 in CLL samples is associated
with reduced differentiation.
Reversal of CLL-cell anergy following culture in vitro is
associated with increased PRDM1 responsiveness
B-cell anergy is antigen dependent and is therefore reversible
following the removal of antigen.15 InCLL, culture in vitro can result
in a reversal of anergy, associated with recovery of sIgM expression
and sIgM signaling capacity, although the extent of reversal is
variable between individual samples.12 To determine if reduced dif-
ferentiation capacitywas also reversible, nonresponsive CLL samples
(n5 8) were cultured in vitro for up to 4 days and analyzed for anti-
IgM–induced iCa21 mobilization and CpG-ODN–induced PRDM1
expression. Consistent with previous studies,12 culture in vitro was
associated with variable levels of recovery of anti-IgM signaling
responsiveness (Figure 5A). Importantly, samples that showed re-
covery of sIgM responsiveness following culture invitro also acquired
the ability to induce expression of PRDM1 following treatment with
CpG-ODN (n5 5; Figure 5B). By contrast, those samples that did not
recover anti-IgM signaling capacity (n 5 3), also did not recover
PRDM1 responsiveness. Variability in recovery may reﬂect different
levels of spontaneous apoptosis in CLL cultures, which, if extensive,
would preclude functional recovery.
Mechanisms of reduced differentiation capacity in anergic
CLL cells
We performed a series of experiments to determine the mechanisms
that caused reduced PRDM1 induction in CLL cells. Analysis of
IL-21R expression by ﬂow cytometry demonstrated that IL-21 res-
ponsiveness was unrelated to changes in expression of the IL-21
receptor (supplemental Figure 5A), and we therefore focused on
downstream signaling responses.
We analyzed two transcription factors that are modulated by IL-21
and CpG-ODN, namely, signal transducer and activator of
transcription 3 (STAT3) and NF-kB. STAT3 is important for PC
differentiation following treatment with both IL-21 and
CpG-ODN,36,37 and NF-kB activity is essential for both IL-21 and
CpG-ODN–induced PRDM1 expression in differentiation-competent
CLL cells (supplemental Figure 5B). The activation of these
transcription factors was analyzed at up to 6 hours poststimulation
with IL-21 or CpG-ODN, a time point at which an increase in PRDM1
expression was observed in responsive samples. Increased activation
of STAT3 and NF-kB (measured by analysis of STAT3 Y705
phosphorylation38 and increasedDNA-binding activity of the p65NF-
kB subunit, respectively [Figure 6A-B], increased expression of
downstream target genes [MCL1 for STAT3] [Figure 6A], and IkBa
and IkBz for p65 NF-kB [Figure 6C]) was observed in all samples,
regardless of whether they were differentiation competent.
These data suggested that the mechanism that led to reduced
PRDM1 induction acted downstream of activation of proximal
signaling events triggered by IL-21 or TLR9. To conﬁrm this, we
determined whether reduced differentiation could be circumvented
using pharmacologic agents. We treated cells with PMA and/or
ionomycin. In responsive CLL samples, PMA alone was sufﬁcient
to induce PRDM1 expression, although to a lower extent than
CpG-ODN, and thiswasmodestly enhanced by ionomycin (Figure 6D).
By contrast, PMA6 ionomycin did not induce PRDM1 expression
in CLL samples that were unable to induce PRDM1 expression
following treatment with IL-21 or CpG-ODN.
Lack of PRDM1 induction is associated with altered epigenetic
regulation of the PRDM1 gene
Because variable induction of PRDM1 in different CLL samples was
not due to differences in activation of upstream signal transduction
pathways, we focused directly on transcriptional control of PRDM1
at the gene level. We treated CLL samples with IL-21 1 CD40L or
with CpG-ODN for up to 4 and 15 hours, respectively, and quantiﬁed
the level of PRDM1a messenger RNA (mRNA) by quantitative
polymerase chain reaction (Figure 7Ai-ii). Analysis focused on
quantifyingPRDM1amRNAbecause this encoded themost abundant
PRDM1 protein isoform detected in IL-21/CpG-ODN–stimulated
cells. Increased levels of PRDM1a mRNA were detected in re-
sponsive samples, with levels showing a steady increase following
stimulation with IL-21 1 CD40L (Figure 7Ai), but a delayed (.3
hours) induction following treatment with CpG-ODN (Figure 7Aii).
In contrast, PRDM1a mRNA was not induced in nonresponsive
samples at any time point. Similar results were obtained when we
analyzed expression of “unspliced” (precursor) PRDM1a RNA
in CpG-ODN–treated cells (supplemental Figure 6A). Reduced
Figure 5. Reversal of anergy following culture in vitro is associated with
recovery of PRDM1 induction in nonresponsive CLL samples. Nonresponsive
CLL samples (n 5 8) were left to “recover” in vitro for up to 4 days, and then, (A)
iCa21 mobilization following anti-IgM treatment was measured. The time of anti-IgM
stimulation (down arrow) and the set threshold above which the percentage of
responsive cells was calculated (dotted line) are shown. (B) Induction of PRDM1
after treatment with CpG-ODN for 16 hours was measured by western blot. Levels of
PRDM1 in a responsive CLL clone treated with CpG-ODN for 16 hours are shown for
comparison.
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induction of PRDM1 protein is, therefore, likely to be due to pre-
transcriptional regulatory mechanisms.
We next investigated whether decreased PRDM1 transcription
was linked to epigenetic mechanisms by investigating both DNA
methylation and histone modiﬁcations associated with PRDM1 tran-
scriptional control elements. Although PRDM1 expression can be
inhibited by DNA methylation at its transcription start site (TSS),39
we detected no evidence for this modiﬁcation in 3 responsive and
3 nonresponsive samples (a total of 41 CpG sequences analyzed
between2349 bp and1251 bp from the TSS for each sample; data
not shown). To investigate if the variability in PRDM1 expression
was due to epigenetic reprogramming, we performed ChIP analysis
and observed that chromatin marks associated with active transcrip-
tion, namely, H3K9/K14 acetylation or H3K4 trimethylation40,41
were higher at the TSS in responsive CLL samples compared with
nonresponsive samples (Figure 7Bi-ii). Abundance of these marks
increased following treatment with CpG-ODN in both responsive
and nonresponsive CLL cells, but the increase in H3K4me3 was
signiﬁcantly higher in responsive samples (P 5 .009).
Thus, the inability of nonresponsive CLL cells to induce
PRDM1 is likely the result of transcriptional repression and failure
to facilitate gene transcription through appropriate chromatin mod-
iﬁcations. Occupancy of the proximal promoter by appropriately
modiﬁed RNA polymerase II dictates transcription as “paused” or
“poised”.42 To ascertain the status of the PRDM1a gene, we
performed a ChIP analysis and demonstrated that the promoter is
“poised,” and initiated for transcription in both response types, as
characterized by similar binding of Ser5-phosphorylated RNA
polymerase II to its TSS43 (supplemental Figure 6B). As further
evidence of the “poised” state, H3K27me3 at the TSS was similar
in all cases studied (not shown). To conclude, the transcriptional
inactivity of the PRDM1 gene is due to transcriptional “re-
pression” and not silencing.
Discussion
Signaling via the BCR is considered to play a major role in deter-
mining variable clinical behavior in CLL, a conclusion that is
Figure 6. Downstream mediators of receptor
signaling remain functional in nonresponsive
CLL samples. (A) CLL samples were treated for up
to 6 hours with IL-21 and lysates examined by
western blot. Induction of PRDM1a, STAT3 Tyr-
phosphorylation (pY-STAT3), and MCL1 are shown.
Total STAT3 and b-actin were used as loading
controls. Representative responsive and nonre-
sponsive CLL samples are shown. (B) Three re-
sponsive (R) and nonresponsive (NR) CLL samples
were harvested directly after thawing, or after 2 or
20 hours of treatment with and without CpG-ODN.
Nuclear extracts were then subjected to an NF-kB
p65 subunit ELISA. (C) Induction of IkBa and IkBz
RNA following treatment with CpG-ODN (for up to
15 hours) in 3 R and 4 NR-CLL samples. (D) CLL
cells were left untreated or treated with CpG-ODN,
PMA (50 ng/mL), or PMA and ionomycin (50 ng/mL and
1 mg/mL, respectively). Cell lysates were then western-
blotted and probed for PRDM1a. Representative of
(n 5 3 each) R- and NR-CLL samples.
Figure 7. Persistence of PRDM1 a transcriptional repression in nonresponsive
CLL samples is a result of failure to induce high levels of activating histone
modifications. (A) Responsive and nonresponsive CLL samples were treated with:
(i) IL-21 1 CD40L, or (ii) CpG-ODN and PRDM1a RNA was quantified using
quantitative polymerase chain reaction at times up to 4 and 15 hours, respectively.
Case numbers are shown in the top left-hand corner of each graph. (B) ChIP
experiments showing: (i) H3K9Ac/K14Ac (H3Ac), or (ii) H3K4me3 at the PRDM1
TSS before and after treatment of responsive (R; n5 3) and nonresponsive (NR; n5 3)
samples with CpG-ODN. *P 5 .009.
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consistentwith the dramatic clinical responses that have been reported
for novel compounds that target BCR-associated kinases. The major
consequence of antigen engagement in CLL appears to be anergy,
which is observed to a variable extent in all CLL samples.1 However,
potentially low levels of positive signalingmay tip the balance toward
cell-survival and division, and disease progression.16,17,44 In mouse
B cells, anergy is associated with reduced differentiation capacity
to limit the production of potentially pathogenic autoantibodies.14
Recent studies of potential anergic B-cell populations in healthy
humans have demonstrated that these cells are also hyporesponsive
to differentiation-promoting signals.45 Differentiation capacity of
CLL cells is varied,21,22,46-50 although it is not known whether this is
related to anergy in these cells.
In this study,wedemonstrated that variable differentiation capacity
of CLL cells is linked to their anergic phenotype with strong anergy
associated with markedly reduced differentiation capacity. Anergy is
dependent on continued antigen engagement of BCRs, and like down-
modulated sIgM,12 reduced differentiation capacity is reversed
following culture in vitro. Our molecular studies revealed that
decreased differentiation capacity was associated with transcriptional
repression of PRDM1 expression. This transcriptional repression
appeared to involve epigenetic reprogramming, a novel observation
with potential relevance for understanding B-cell anergy not just in
CLL, but also in nonmalignant cells. Given the key role of PRDM1 in
controlling differentiation, and as a common node for reception of
diverse differentiation-promoting transduction pathways, epigenetic
suppression of PRDM1 transcription would be an effective mecha-
nism to broadly and selectively suppress differentiation.
Although IL-21 and CpG-ODN have profound effects on normal
B-cell differentiation, their effects on CLL-cell differentiation have
not been investigated in detail. One recent study also demonstrated
intrasample variation in CpG-ODN–induced differentiation of CLL
samples.23 Although not shown in the study, the authors stated that
there was a trend to increased CpG-ODN–induced differentiation in
U-CLL, which could reﬂect the impact of anergy that we describe
here because anergic features are most prominent in M-CLL. One
other study stated that IL-21 did not induce PRDM1 expression in
CLL cells, but as this particular component of theworkwas restricted
to just two samples, this could represent the subset of nonresponsive
samples identiﬁed in this work.32
Although our study focused on differentiation, it was important to
discoverwhether variable responseswere speciﬁc for differentiation,
or could be linked to, or is a consequence of, alterations in survival
and proliferation. The published literature on proliferative and
apoptotic responses of CLL cells following treatment with IL-21 or
CpG-ODN is complex. Some studies have demonstrated that IL-21
promotes apoptosis in a proportion of CLL samples, although this
response has not been linked to speciﬁc subsets of disease.33,35,51 By
contrast, other studies have described variable effects onproliferation,
with little effect on cell death, potentially linked to IGHV status
(enhanced IL-21–induced proliferation in M-CLL).32 Variation has
also been described for CpG-ODN responses.34 To investigate the
relationship between these responses and differentiation,we analyzed
the effects of IL-21/CpG-ODN on survival and proliferation in a
deﬁned cohort of samples with distinct PRDM1 responsiveness. Con-
sistent with the literature, effects of IL-21 on apoptosis were variable,
whereasCpG-ODNconsistently promoted survival.However, the key
observation was that variation in apoptosis responses was clearly
unrelated to PRDM1 induction, indicating that these responses are
uncoupled. In contrast, responsive CLL cases were signiﬁcantly more
likely to exhibit a proliferative phenotype. Repression of both IL-21/
CpG-ODN–induced proliferation and differentiation in anergic CLL
cells may not be surprising insofar as both proliferation and differen-
tiation of B cells are required for antibody responses.
The role of transcription in B-cell anergy has been a subject of
debate. It is clear that B-cell anergy is associated with changes in gene
expression compared with naive or acutely stimulated cells,52 and
transcription factors such as nuclear factor of activated T cells 1 play
essential roles in maintaining anergy.53 However, some features of
anergy are rapidly reversible following removal of the anergizing
antigen.15 The kinetics of this responsewould appear to preclude a role
for transcriptional reprogramming, at least in modulation of initial
sIgMsignaling capacity.However, it is possible that other components
of the anergic phenotype do depend on transcriptional regulation. In
anergic T cells, silencing of the IL2 and IFNG loci is associated with
epigenetic reprogramming through changes in histone acetylation and
methylation.54 Regardless, further studies of CLL cells may shed new
light on molecular mechanisms of anergy with relevance not just for
the biology of normal and malignant B cells, but also for autoimmune
disorders characterized by a breakdown in B-cell tolerance.
Overall, these studies extend our understanding of the consequen-
ces of antigen engagement in CLL and demonstrate that reduced
differentiation capacity of CLL cells is an additional feature linked
to the anergic phenotype of these cells. Further study is required to
explore the in vivo relevance of our ﬁndings. Since all CLL samples
show some evidence for anergy, our observationsmay explain the lack
of robust differentiation of CLL cells in vivo despite recent evidence
for IL-21 and autologous T-cell–induced proliferative signals.32,55
However, there is some evidence for low levels of differentiation in
some patients, revealed by low level PRDM1 expression in a small
subset of lymph nodes from patients with CLL/small lymphocytic
lymphoma.56 Moreover, CLL cells are known to secrete variable
levels of IgM1 and paraproteins are detected in some patients. The
clinical signiﬁcance of these features remain unclear, but it will be
interesting to determine whether they are more frequent in the less
anergizedU-CLL subset. Differentiation-promoting therapies are well
established in acute leukemias and have been suggested as a potential
strategy for CLL.23,57,58 Because CLL cells do appear to retain a latent
potential for differentiation, and our results indicate that the PRDM1
locus is transcriptionally “poised,” it is likely amenable to derepression
to promote terminal differentiation and apoptosis. Our results are
important in this regard because the residual differentiation capacity
appears to rest within the less anergized subsets of disease, which
generally have a poorer prognosis, and where there is a pressing need
for new or adjuvant treatment approaches.
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